Cytokinetics had its Relative Strength (RS) Rating upgraded from 78 to 81 Wednesday.
Risk Management In The Stock Market: How Much Money To Invest Now
This unique rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains typically have an 80 or better RS Rating as they launch their biggest climbs.
Cytokinetics is not currently near a potential buy zone. See if the stock goes on to build a promising consolidation that could kick off a new climb.
The company showed 0% EPS growth in its most recent report, while sales growth came in at 26,608%.
The company holds the No. 191 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
